Autolus engineers a $100M-plus IPO for itself as it blueprints a new generation of better, safer cell therapies
The London-based T cell engineers at Autolus are steering the company to a $100 million-plus IPO, hoping to bank on a so far insatiable appetite for a new generation of cell therapies built to outstrip the pioneers in the market.
Helmed by Micromet vet Christian Itin, Autolus has been touting its early-stage approach to CD19 binding with a quick disengagement strategy that they believe will greatly reduce the risk of cytokine storms that frequently afflict patients — a toxicity that has limited their initial use.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
